Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis

This study has been completed.
UCB Japan Co. Ltd.
Information provided by (Responsible Party):
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
First received: September 25, 2011
Last updated: July 21, 2015
Last verified: July 2015

The objective of this study is to assess the efficacy of CDP870 with MTX compared with MTX-alone in early MTX-naive RA patients with poor prognosis, using inhibition of radiographic progression in joints over a one-year period as a primary endpoint. Following a year of treatment with CDP870 plus MTX treatment, CDP870 will be discontinued, and the subjects will be monitored for one more year (the follow up period) to investigate the sustainability of efficacy of CDP870 during the MTX monotherapy for exploratory purpose.

Condition Intervention Phase
Rheumatoid Arthritis
Drug: placebo
Drug: CDP870
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Early MTX-naive Rheumatoid Arthritis Patients With Poor Prognosis

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Inhibition of radiographic progression [ Time Frame: week 52 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Inhibition of radiographic progression [ Time Frame: week 24 ] [ Designated as safety issue: Yes ]
  • Clinical remission rate [ Time Frame: week 24 , week 52 ] [ Designated as safety issue: No ]

Enrollment: 316
Study Start Date: October 2011
Study Completion Date: October 2014
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo given every 2 weeks
Drug: placebo
Subcutaneous (SC)
Experimental: CDP870
400 mg CDP870 given at Week 0, 2, 4, and thereafter 200 mg CDP870 given every 2 weeks
Drug: CDP870

Detailed Description:

This study was initiated by Otsuka Pharmaceutical Co., Ltd and transferred to Astellas on 12/04/2012.


Ages Eligible for Study:   20 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with RA as defined by the ACR/EULAR criteria (2010) who meet all of the following criteria.

    1. Subjects who developed RA within one year.
    2. Subjects who have never received MTX before (MTX naive)
    3. Subjects whose disease activity is moderate or more (DAS28(ESR) > 3.2)
    4. Subjects must satisfy at least two of the three criteria (Anti-CCP antibody positive, Rheumatoid factor positive, Presence of X-ray erosion) for poor prognosis. The anti-CCP antibody positive is essential for every patient.

Exclusion Criteria:

  • Patients who have a diagnosis of any other type of inflammatory arthritis.
  • Patients who have a secondary, non-inflammatory type of arthritis.
  • Patients who have used with MTX, reflunomide, or any other biologics prior to the start of study drug administration.
  • Patients who have NYHA (New York Heart Association) Class III or IV congestive heart failure
  • Patients who currently have, or who have a history of, tuberculosis.
  • Patients who have a high risk of infection (with a current infectious disease, a chronic infectious disease, a history of serious infectious disease)
  • Patients who currently have, or have a history of, malignant tumor
  • Female patients who are breastfeeding or pregnant, who are of childbearing potential
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01451203

Chubu Region, Japan
Chugoku Region, Japan
Hokkaido Region, Japan
Kanto Region, Japan
Kinki Region, Japan
Kyushu Region, Japan
Shikoku Region, Japan
Tohoku Region, Japan
Sponsors and Collaborators
Astellas Pharma Inc
UCB Japan Co. Ltd.
  More Information

No publications provided

Responsible Party: Astellas Pharma Inc
ClinicalTrials.gov Identifier: NCT01451203     History of Changes
Other Study ID Numbers: CDP870-275-11-001, JapicCTI-111636
Study First Received: September 25, 2011
Last Updated: July 21, 2015
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Astellas Pharma Inc:
Early RA
Certolizumab Pegol

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Certolizumab pegol
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 27, 2015